Key result
Induction therapy significantly decreased serum visfatin levels from 4.6 ng/mL to 2.5 ng/mL in patients with active inflammatory bowel disease, while leptin, adiponectin, and resistin showed no significant alterations.
Why the study?
Does induction therapy reduce circulating adipokine levels in patients with active inflammatory bowel disease?
Observational (n=34)
No
Does induction therapy reduce circulating adipokine levels in patients with active inflammatory bowel disease?
Visfatin levels decrease significantly after induction therapy in active inflammatory bowel disease, suggesting its potential role as a marker of successful therapy.
Visfatin reduction may mark IBD treatment response; leaves open its value for cardiovascular risk monitoring in these patients.
Background/Aims: The aim of this study was to evaluate the change in circulating levels of adipokines, including leptin, adiponectin, resistin, and visfatin, after induction therapy of patients with active inflammatory bowel disease (IBD).Methods: We prospectively evaluated 20 patients with Crohn's disease (CD) and 14 patients with ulcerative colitis (UC) who received induction therapy.The disease activity, body mass index (BMI), and C-reactive protein (CRP) and serum adipolines levels were checked before treatment and 10 weeks after treatment.Results: After induction therapy, significant reduction of disease activity was noted in patients with CD (CD activity index, 267.9±73.7 vs. 50.8±36.5,P＜0.001) and patients with UC (Mayo score, 9.8±2.2 vs. 1.4±1.6,P＜0.001).The mean serum leptin, adiponectin, resistin, and visfatin levels were 4.0±2.7 ng/mL and 4.4±2.3ng/mL (P=0.323),27.0±20.5μg/mL and 33.8±26.5μg/mL(P=0.084),9.0±4.0ng/mL and 10.2±3.2 ng/mL (P=0.108), and 4.6±3.7 ng/mL and 2.5±4.1 ng/mL (P=0.046)before and after infliximab treatment, respectively.No significant correlation between the changes in BMI, CRP level, or the clinical indices of activity and alterations of the measured adipokines was demonstrated.Conclusions: The serum levels of leptin, adiponectin, and resistin showed no significant alterations, whereas the serum visfatin level decreased significantly after induction therapy, suggesting a possible pro-inflammatory property of visfatin and a role as a marker of successful therapy of IBD.(Intest Res 2010;8:151-161)
No takes yet. Share an insight, caveat, or question.
Hwangbo et al. (2010) conducted an observational in Active inflammatory bowel disease (n=34). Induction therapy vs. Baseline was evaluated on Serum visfatin level (ng/mL) (p=0.046). Induction therapy significantly decreased serum visfatin levels from 4.6 ng/mL to 2.5 ng/mL in patients with active inflammatory bowel disease, while leptin, adiponectin, and resistin showed no significant alterations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: